Skip to main content
. 2018 Sep 20;19(10):2846. doi: 10.3390/ijms19102846

Figure 2.

Figure 2

CMS-2, but not CMS-1, treatment reduces cell viability of murine melanoma and melanocyte. Cell viability was evaluated by Resazurin metabolism after 24 h of CMS-1 or CMS-2 exposure (0.5–100 µg/mL) in: B16-F10 (A,C), respectively; or Melan-a (B,D), respectively. Absorbance of Resazurin metabolite was spectrophotometrically quantified (570/600 nm) and half maximal inhibitory concentration (IC50) was determined through non-linear regression of Log concentration versus absorbance (E). (F,G) Representative images of B16-F10 treated with 10 µg/mL CMS-2 after 24 h. CMS-2 treated cells (G) are more circular, quantified in (H), fusiform and dendritic compared to the control (F). (H) Cell circularity was quantified in B16-F10 cells treated with CMS-2 using ImageJ software. **** p < 0.001, t-test, compared to B16-F10 control.